Relapsed/Refractory Follicular Lymphoma research hub
5 indexed studies · 2 currently recruiting
- recruitingPHASE3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
This study is testing new treatments for two types of lymphoma, follicular and marginal zone lymphoma, when they have come back or not responded to previous treatment. It compares a drug called zanubrutinib combined with other medicines against a standard treatment to see which works best.
United States · Argentina · Australia - active not recruitingPHASE3
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
This study is looking at a new treatment called axicabtagene ciloleucel for follicular lymphoma that has come back or hasn't responded to other treatments. It compares this new treatment to standard care to see how well it works.
United States · France · Germany - recruitingPHASE3
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
This study looks into a new treatment for follicular lymphoma and marginal zone lymphoma that have returned or didn't respond to previous treatments. It combines a new drug, odronextamab, with an existing one, lenalidomide, and compares it to a standard treatment.
United States · Australia · Austria - ongoing, recruitingTherapeutic exploratory (Phase II)
An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma
This study looks at a new drug, zanubrutinib, combined with obinutuzumab, for people with follicular lymphoma that has come back or not responded to previous treatment. It compares this combination with obinutuzumab alone, to see if the new combination works better.
France · Czechia · Italy - active not recruitingPHASE3
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
This study is for adults with a type of blood cancer called follicular lymphoma, which has come back or isn't responding to treatment. It compares a new drug (Tazemetostat) with existing treatments to see if it's safe and helps people live longer without their cancer getting worse.
United States · Australia · Belgium